Goldman Sachs Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $44

Benzinga · 5d ago
Goldman Sachs analyst Salveen Richter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $51 to $44.